Prospective Comparison of Phenpocoumon (Marcumar) and Acetylsalicylic Acid (ASS) as to Progression of the Valvular and Coronary Calcification. - ASS-Marcumar

RWTH Aachen University0 个研究点目标入组 120 人开始时间: 2007年11月13日最近更新: 2021年3月30日

适应症

试验速览

暂无简介。

•- Caucasian from 50 to 90 years
•- BMI from 19 to 27 kg/m²
•- (1) Patients with newly induced antcoagulation with Phenprocoumon, planned for at least 1 year. The most frequent indication for a Phenprocoumon thearpy are atrial fibrillation, heart valve replacement, and a strongly restricted LV function
•- or (2) control collective with the standard ASS therapy (100mg/d). The most frequent indication for this therapy is the coronary artery disease
•- persons, who are sui juris and mentally able to understand and follow the instructions of the study staff
•- signed informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 60

•- renal insuffiency stage IV or V
•- acute cardiac or pulmonary decompensation
•- increased serum level of calcium
•- women of childbearing age or present pregenancy or lactation
•- psychiatric disease
•- individuals, who are accomodated in an instution on juridicial or official order
•- life expectancy <1 year
•- acute life-threatening condition of the patient
•- Individuals, who have a relationship of dependency to or work for the sponsor or the investigator
•- simultaneous participation in another clinical trial

发起方